Shares in Cerus (NSDQ:CERS) fell today despite the company beating expectations on Wall Street with its second quarter results.
The Concord, Calif.-based company posted a net loss of -$17.1, or -16¢ per share, on sales of $9.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales growth of 3% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.